Cardiac Biomarkers to Refine Pre-Test Probability for Coronary Obstruction and Predict Survival after Revascularisation in Chronic Coronary Syndrome

Teren Andrej [a, b], Netto Jeffrey [b,c,e], Thiery Joachim [b,d,e], Thiele Holger [f], Stellbrink Christoph [a], Lawin Dennis [a], Lawrenz Thorsten [a], Derda Anselm [a,g], Henger Sylvia [b,h], Kirsten Holger [b,h], Scholz Markus [b,h], Kaiser Thorsten [b,c,e]

[a] Department of Cardiology and Intensive Care Medicine, Bielefeld University, Klinikum Bielefeld Mitte, Bielefeld, Germany

[b] Leipzig Research Centre for Civilisation Diseases (LIFE), University of Leipzig, Leipzig, Germany

[c] Institute for Laboratory Medicine, Microbiology and Pathobiochemistry, University Hospital Ostwestfalen-Lippe (UK-OWL), Campus Klinikum Lippe, Bielefeld University, Bielefeld, Germany

[d] Faculty of Medical, Christian-Albrechts-University Kiel, Kiel, Germany

[e] Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany

[f] Department of Internal Medicine/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany

[g] Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

[h] Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany

Running head: Cardiac Biomarkers in CCS: Diagnosis and Prognosis

Corresponding author:

Dr. Andrej Teren
Department of Cardiology and Intensive Care Medicine
Bielefeld University
Medical School and University Medical Centre OWL
Klinikum Bielefeld – Mitte
Teutoburger Str. 50
33604 Bielefeld
Germany
Telephone: +49-521-581-3426
Telefax: 0521 581-3498
E-mail: andrej.teren@klinikumbielefeld.de

Word count: 249 words (abstract), 4,410 words (overall)

ABSTRACT

Background and aims

The utility of cardiovascular and inflammatory biomarkers to detect coronary obstruction and predict survival benefit of revascularisation in chronic coronary syndrome (CCS) remains unclear.

Methods

Patients undergoing coronary angiography for suspected CCS were studied. High-sensitivity cardiac troponin T (hsTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and copeptin were measured. Diagnostic performance to detect anatomical coronary stenosis (i.e. ≥50%) was assessed using Receiver Operating Characteristic (ROC) analysis with Net Reclassification Improvement (NRI). Survival analysis using multivariate Cox regression assessed treatment-stratified biomarker performance and biomarker × treatment interaction.

Results

Among 2,251 patients, 888 (39.4%) had coronary obstruction. Only hsTnT provided meaningful diagnostic capacity (Area Under the Curve; AUC 0.669), comparable with risk factor-weighted clinical likelihood (RF-CL) estimate recommended by the current guidelines (AUC 0.663). Reclassification value demonstrated an inverse relationship to RF-CL: very low (NRI=38.4%), low (NRI=19.3%), and intermediate/high likelihood (NRI=12.4%). NT-proBNP was the strongest universal mortality predictor across all treatment categories: Optimal Medical Therapy (OMT; HR 1.488, 95%CI:1.288-1.720,

p<0.001), Percutaneous Coronary Intervention (PCI; HR 1.220, 95%CI:1.020-1.458, p=0.029), Coronary Artery Bypass Grafting (CABG; HR 1.220, 95%CI:1.049-1.420, p=0.010). Interaction analysis (p=0.024) demonstrated that in patients with NT-proBNP <150 pg/mL the revascularisation group has an improved survival (HR 0.64, 95%CI:0.47-0.87, p=0.005), whilst this was not observed for the patients with NT-proBNP ≥150 pg/mL (HR 0.96, 95%CI:0.71-1.30, p=0.782).

Conclusions

HsTnT provides meaningful diagnostic value with RF-CL category-specific incremental benefit following an inverse gradient pattern. The NT-proBNP 150 pg/mL threshold identifies patients with improved survival after revascularisation.

Clinical Trial Registration: ClinicalTrials.gov NCT00497887

Keywords: *chronic coronary syndrome, pre-test probability, troponin, B-type natriuretic peptide, revascularisation.*

KEY LEARNING POINTS

What is already known:

- Cardiac biomarkers predict outcomes in chronic coronary syndrome

- ESC 2024 guidelines introduced risk-factor weighted clinical likelihood assessment

- The incremental value of biomarkers to detect coronary stenosis and guide risk stratification after revascularization remains uncertain

What this study adds:

- High-sensitivity troponin T diagnostic utility follows an inverse gradient pattern, with greatest incremental benefit in very low baseline risk patients

- NT-proBNP <150 pg/mL identifies a patient subgroup with significant survival improvement after revascularisation

- Cardiac biomarker patterns provide biological validation of ESC 2024 guideline evolution

INTRODUCTION

Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, with chronic coronary syndrome (CCS) representing a significant clinical burden (1,2). Accurate detection of coronary obstruction and prediction of long-term outcomes remain challenging (3,4).

Current diagnostic approaches rely on clinical assessment, non-invasive imaging, and invasive coronary angiography, with inherent limitations (6). The 2024 European Society of Cardiology (ESC) guidelines introduced a revised pre-test probability (PTP) model based on risk factor – weighted clinical likelihood (RF-CL) incorporating additional risk factors (i.e. diabetes, smoking, dyslipidemia, hypertension, and family history) beyond the traditional age-sex-symptom triad (2). Direct comparison of novel biomarker-based approaches to improve the predictive value of guideline-recommended PTP models remains limited. Moreover, differences in revascularisation benefit between CCS and myocardial infarction patients highlight the need for tailored therapeutic and secondary-preventive strategies (5).

Cardiac-specific biomarkers High-sensitivity cardiac troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have demonstrated proven utility in acute myocardial infarction (MI), and partially in CCS settings (6,7, 15). NT-proBNP, in particular, represents a cornerstone biomarker across the entire spectrum of cardiovascular diseases, demonstrating strong diagnostic and prognostic value in heart failure patients from acute decompensation through chronic stable disease, with guideline-recommended thresholds for diagnosis and risk stratification (7). In CCS, these biomarkers may serve dual roles in both diagnostic and prognostic applications.

Inflammatory biomarkers high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6), and copeptin also warrant systematic investigation, as these biomarkers may offer incremental value in both diagnostic assessment and prognostic stratification of CCS patients (3,8).

This study aimed to evaluate the diagnostic performance of five circulating biomarkers against 2024 PTP model, assesses incremental diagnostic value stratified by baseline risk categories, and determines prognostic utility across different treatment strategies to identify biomarker thresholds predicting long-term survival after revascularisation.

METHODS

Study Design and Population

This analysis utilized data from the Leipzig Research Centre for Civilization Diseases - Heart study (LIFE-Heart study), a longitudinal cohort examining patients with suspected CCS at the Heart Center Leipzig at Leipzig University. The study aimed to identify genetic, biochemical, and environmental markers associated with coronary and extracoronary atherosclerosis development (9). The protocol adhered to Declaration of Helsinki principles and was approved by the Ethics Committee of the Medical Faculty, University of Leipzig (registration 276-2005; ClinicalTrials.gov NCT00497887). Written informed consent was obtained from all participants.

We here consider a subset of LIFE-Heart comprising 3,305 patients (2,122 males, 1,183 females) with suspected CCS based on clinical symptoms or positive non-invasive testing, undergoing first-time coronary angiography. Exclusion criteria for the present

analysis included acute myocardial infarction, pregnancy, lactation, and severe systemic diseases (autoimmune diseases with immunomodulatory therapy, dialysis-requiring conditions, infectious diseases, and malignancy or cancer treatment within two years).

After excluding further 1,054 patients (821 for incomplete clinical symptoms and cardiovascular risk factor assessment, 121 for indeterminate angiographic findings, 112 for hsTnT $\geq$52 pg/mL), 2,251 patients were eligible for the present analysis. Median follow-up was 12.6 years (range 0.1-16.2 years).

Assessment of Cardiovascular Risk Factors and Coronary Status

Traditional atherosclerotic risk factors were evaluated through standardized clinical interviews, biometric assessments, and laboratory analyses. Key comorbidities considered as confounding variables included diabetes mellitus (i.e. history of diabetes mellitus, or HbA1c $\geq$ 6.5%), obesity (i.e. BMI $\geq$ 30 kg/m²), dyslipidemia (i.e. history of dyslipidemia or administration of lipid-modifying agents – ATC group C10), hypertension (i.e. history of arterial hypertension, administration of antihypertensives, or current blood pressure $\geq$ 140/90 mmHg), and impaired renal function i.e. estimated glomerular filtration rate (eGFR) applying CKD-EPI formula < 90 mL/min/1.73 m². Medications were recorded according to Anatomical Therapeutic Chemical (ATC) classification codes.

Coronary angiography was performed following institutional protocols. Participants were stratified based on angiographic findings considering $\geq$50% luminal reduction as significant coronary obstruction. In order to refine the adjustment for angiographic extent of CAD, number of vessels with coronary obstruction and Gensini

score was calculated using predefined standards (10). The selection of coronary therapeutic modality in case of relevant coronary obstruction, i.e. Optimal Medical Therapy (OMT), Percutaneous Coronary Intervention (PCI), or CABG (Coronary Artery Bypass Grafting), was determined at clinical discretion of the physician performing the index coronary angiography.

Laboratory Procedures

Venous blood samples were collected prior to interventional procedures and transported at 4°C to the laboratory within five hours. Samples underwent immediate centrifugation, analysis, and storage in liquid nitrogen gas phase. All procedures followed ISO 15189 and ISO 17025 standards.

Standard lipid profile i.e. low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) and plus serum creatinine were analyzed according to LIFE-Heart protocol (10). Five biomarkers were selected for comprehensive evaluation based on their established pathophysiological relevance and clinical utility in cardiovascular disease: cardiac-specific markers (hsTnT, NT-proBNP) representing myocardial injury and wall stress, inflammatory markers (hsCRP, IL-6) reflecting atherosclerotic disease activity, and copeptin as a marker of chronic neurohumoral activation. HsTnT, NT-proBNP, hsCRP, and IL-6 were measured by electrochemiluminescence on a Roche Cobas 8000 analyzer (Roche Diagnostics, Mannheim, Germany). Serum copeptin was determined using immunological trace technology (ThermoFisher/Brahms, Waltham, MA, USA).

To ensure that biomarker measurements reflected chronic cardiovascular disease states rather than acute clinical conditions, we implemented predefined upper threshold exclusions. Patients with NT-proBNP ≥1000 pg/mL were excluded to eliminate those with acute decompensated heart failure, as this threshold represents the established diagnostic cutoff for acute heart failure in the ESC guidelines (7). Copeptin values ≥13.8 pmol/L were excluded to eliminate potential cases of diabetes insipidus or acute severe illness, as this threshold approximates diagnostic cutoffs for posterior pituitary dysfunction (11). For inflammatory markers, we excluded patients with hsCRP ≥10 mg/L and IL-6 ≥43.5 pg/mL to eliminate acute inflammatory states, infections, or acute phase reactions that would confound assessment of chronic cardiovascular inflammation.

Statistical Analysis

Statistical analyses were performed using SPSS version 29.0 and R statistical software. Continuous variables are presented as medians with interquartile ranges; categorical variables as frequencies and percentages. Patients were dichotomized based on angiographic findings: obstructive CAD (i.e., ≥50% stenosis in at least one major epicardial vessel) versus no or non-obstructive disease (i.e., <50% stenosis).

Pre-test probability was assessed using RF-CL (i.e. age, sex, symptoms, diabetes, current smoking, dyslipidemia, hypertension, family history of premature CAD defined as MI or coronary revascularisation before age 60 years in first-degree relative). In order to examine the incremental discrimination value of biomarkers patients were subsequently categorized based on RF-CL as: Category 1 – very low likelihood (PTP <5%), Category 2 – low likelihood (5-15%), Category 3 – intermediate / high likelihood

(>15%) of relevant coronary obstruction. The more comprehensive cardiovascular risk factor (CRF) model included RF-CL variables plus LDL-C, HDL-C, TG, body mass index (BMI), waist-hip ratio (WHR), administration of antihypertensive medication, administration of statins, left ventricular ejection fraction (EF) assessed by standardised transthoracic echocardiography and estimated glomerular filtration rate (eGFR) applying CKD-EPI-Formel.

For diagnostic performance assessment, Receiver Operating Characteristic (ROC) curves were constructed for all five biomarkers. Area Under the Curve (AUC) values with 95% confidence intervals were tested for differences using DeLong's method (12). The biomarker demonstrating meaningful diagnostic performance was then compared directly with RF-CL model. Optimal cutoff was determined using Youden's index (13). Incremental diagnostic value was assessed via Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) across predefined RF-CL categories, with overall categorical NRI calculated across all patients and RF-CL category-specific NRI calculated within each likelihood stratum. Bootstrap validation with 500 iterations established robust confidence intervals (14). Bootstrap internal validation (250 iterations) assessed optimistic bias for data-derived thresholds following Harrell-Steyerberg methodology, re-deriving optimal cutoffs in each bootstrap sample and calculating optimism as the mean difference between apparent and test performance. Model calibration was evaluated using Hosmer-Lemeshow goodness-of-fit test and calibration plots comparing observed versus predicted probabilities across deciles of predicted risk. Brier score assessed overall model performance, with lower scores indicating better calibration. Clinical utility of identified biomarker diagnostic value was evaluated

through decision curve analysis (DCA), quantifying net benefit across threshold probabilities by comparing true positives gained against false positives incurred.

Survival analysis employed Kaplan-Meier curves with log-rank tests and Cox proportional hazards regression to perform safety analysis for false negatives to detect coronary obstruction (i.e. CAD cases reclassified downward based on biomarker profile) and to determine which biomarker provided strongest prognostic discrimination. Patients were stratified by coronary anatomy and treatment strategy, i.e. obstructive CAD patients treated OMT alone vs with PCI, and CABG, respectively.

Cox proportional hazards regression with backward stepwise elimination was performed using differential adjustment strategies: safety analyses for discriminative value to detect coronary obstruction adjusted for RF-CL variables, while prognostic models adjusted for number of vessels with coronary obstruction, Gensini score, and comprehensive cardiovascular risk factors (CRF). Hazard ratios were calculated per 1 SD increase to enable cross-biomarker comparison.

Time-dependent ROC analysis using the survivalROC package in R determined optimal NT-proBNP cutoff for mortality prediction. Cumulative sensitivity and specificity were calculated across biomarker values at 1, 3, 5 and 10 years, with optimal cutoff identified using Youden's index. Bootstrap validation (500 iterations) established confidence intervals. Bootstrap validation (250 iterations) was performed to assess threshold optimism, re-deriving optimal cutoffs in each bootstrap sample using time-dependent ROC analysis for 5-year mortality. NT-proBNP × Treatment interaction was

assessed using likelihood ratio tests comparing models with and without interaction terms, with stratified Cox regression by cutoff level.

All statistical tests were two-sided, and p-values <0.05 were considered statistically significant.

RESULTS

Baseline Characteristics

Among 2,251 patients, 888 (39.4%) had obstructive CAD. Table 1 presents baseline characteristics stratified by angiographic findings. Patients with obstructive CAD were older (median 67 versus 63 years, p<0.001), more frequently male (75.7% versus 60.9%, p<0.001), and exhibited higher prevalence of traditional cardiovascular risk factors.

Biomarker concentrations demonstrated systematic elevation in patients with obstructive CAD. Median hsTnT was 10.0 ng/L (IQR 6.0-16.0) in obstructive CAD versus 7.0 ng/L (IQR 5.0-11.0) in non-obstructive disease (p<0.001). NT-proBNP showed similar gradient: 151 pg/mL (IQR 74-340) versus 98 pg/mL (IQR 49-198), p<0.001. Inflammatory markers exhibited more modest differences.

Obstructive CAD prevalence showed progressive separation across RF-CL categories (low-likelihood 23.6%, intermediate 32.9%, high-likelihood 53.1%) (chi-square p<0.001).

Diagnostic Performance of Biomarkers to detect anatomical coronary obstruction

Comparative ROC analysis across all five biomarkers revealed marked heterogeneity in diagnostic performance for detecting anatomical coronary obstruction. Only hsTnT demonstrated clinically relevant diagnostic capacity with AUC 0.669 (95% CI: 0.644-0.692). NT-proBNP showed modest discrimination with AUC 0.609 (95% CI: 0.585-0.633), whilst inflammatory markers demonstrated limited diagnostic value: hsCRP AUC 0.536 (95% CI: 0.511-0.561), IL-6 AUC 0.547 (95% CI: 0.522-0.572), and copeptin AUC 0.524 (95% CI: 0.499-0.549).

Direct comparison with ESC 2024 PTP model (Figure 1) demonstrated that hsTnT performance was comparable to RF-CL (AUC 0.663, 95% CI: 0.642-0.689, p=0.842 for comparison). The comprehensive CRF model achieved strong baseline performance (AUC 0.731, 95% CI: 0.709-0.753), with hsTnT addition providing limited additional benefit (AUC 0.747, improvement +0.016, p = 0.013; NRI = 1.9%). Optimal hsTnT cutoff by Youden index was 7.0 ng/L (sensitivity 72.4%, specificity 54.0%) (Supplementary Table S1). This threshold provided the basis for incremental value assessment beyond current RF-CL model (Supplementary Table S1). Bootstrap validation (250 iterations) confirmed minimal bias: optimal cutoff median 6.97 ng/L (95% CI: 6.62-8.47), chosen 7.0 ng/L at 70th percentile, AUC optimism 0.001 (optimism-corrected AUC 0.668).

Incremental value of the hsTnT 7.0 ng/L cutoff stratified by RF-CL categories demonstrated an inverse relationship between baseline pre-test clinical likelihood and biomarker benefit (Table 2, Supplementary Tables S1-S2). In very low likelihood patients (RF-CL <5%), hsTnT addition yielded substantial reclassification: categorical NRI 38.4% (95% CI: 28.9-47.8%, p<0.001), and IDI 6.3% (95% CI: 4.8-7.9%, p<0.001).

Low pre-test likelihood patients (RF-CL 5-15%) showed moderate benefit: NRI 19.3% (95% CI: 12.7-26.0%, p<0.001), IDI 4.2% (95% CI: 2.9-5.5%, p<0.001). Intermediate/high likelihood patients (RF-CL >15%) exhibited the smallest incremental value: NRI 12.4% (95% CI: 6.8-18.1%, p<0.001), IDI 2.6% (95% CI: 1.4-3.8%, p<0.001). Accordingly, discrimination improvement showed the same pattern: AUC increased by +0.104 in very low likelihood, +0.080 in low likelihood, and +0.050 in intermediate/ high likelihood category (all p<0.001; Supplementary Table S2).

Model calibration analysis (Supplementary Figure S1A) demonstrated that the RF-CL model showed acceptable fit (Hosmer-Lemeshow χ^2=12.4, p=0.134, Brier score=0.224), with addition of hsTnT ≥7.0 ng/L cutoff improving calibration (χ^2=8.9, p=0.351, Brier score=0.216, ΔBrier=-0.008; p<0.001). Decision curve analysis (Supplementary Figure S1B) revealed that hsTnT provided clinical net benefit across threshold probabilities of 20-60%, with greatest benefit in the 30-45% range.

Reclassification patterns (Supplementary Table S3) showed differential biomarker impact by disease status: among 888 patients with obstructive CAD, 218 (24.5%) were reclassified upward and 228 (25.7%) downward, while among 1,363 patients without obstructive CAD, 521 (38.2%) were appropriately reclassified downward versus 312 (22.9%) upward, yielding overall categorical NRI of +7.59% (event NRI -14.86%, non-event NRI +22.45%) (Supplementary Table S1). Safety analysis (Supplementary Table S4) revealed that unadjusted analysis showed false negative patients (obstructive CAD with hsTnT <7.0 ng/L, n=249) had significantly higher mortality than true negatives (no obstructive CAD with hsTnT <7.0 ng/L) in the very low likelihood category (HR=1.83, 95% CI: 1.16-2.89, p=0.009). However, adjustment for RF-CL risk factor variables

substantially attenuated this apparent excess mortality to non-significance: very low CL (adjusted HR=1.29, 95% CI: 0.81-2.06, p=0.283), low CL (adjusted HR=0.90, 95% CI: 0.53-1.54, p=0.707), and overall (adjusted HR=1.10, 95% CI: 0.77-1.56, p=0.608). RF-CL factors as such (i.e. not used as scoring components in categorical RF-CL model) explained 65-81% of the excess risk, demonstrating that the unadjusted mortality differences were primarily attributable to baseline cardiovascular risk factor burden rather than low hsTnT itself.

Long-Term Survival Outcomes

During median 12.6-year follow-up, 684 deaths occurred (30.4%) in 2,251 patients. Overall survival rates were: no/non-obstructive CAD 74% (95% CI: 72-77%, n=1,363), obstructive CAD with PCI 69% (64-74%, n=344), OMT 64% (58-69%, n=277), and CABG 54% (48-60%, n=267; log-rank p<0.001). No/non-obstructive CAD patients had significantly better survival than all obstructive CAD groups (all p≤0.016), PCI showed superior survival versus both OMT (p=0.038) and CABG (p<0.001), while OMT and CABG did not differ significantly (p=0.16). Figure 2 presents full-adjusted Cox regression hazard ratios across patient subgroups. NT-proBNP demonstrated universal prognostic utility across all categories with consistent effect magnitudes. Per 1 SD increase, NT-proBNP conferred increased mortality risk: OMT HR 1.488 (95% CI: 1.288-1.720, p<0.001), PCI HR 1.220 (95% CI: 1.020-1.458, p=0.029), CABG HR 1.220 (95% CI: 1.049-1.420, p=0.010).

Other biomarkers showed inconsistent prognostic associations. HsTnT and hsCRP maintained significance in OMT and non-obstructive CAD but not in revascularised

patients. Notably, copeptin demonstrated the strongest prognostic association in CABG patients (HR 1.389, 95% CI: 1.130-1.697, p=0.001), exhibiting the highest hazard ratio among all biomarkers in this treatment subgroup.

Time-dependent ROC analysis across multiple follow-up time points (1, 3, 5, and 10 years) was performed separately for PCI (n=344, 108 deaths) and CABG (n=267, 99 deaths) subgroups using Youden's Index optimization. Optimal NT-proBNP cutoffs varied across time points: PCI subgroup ranged from 119.4 pg/mL (5-year) to 233.1 pg/mL (1-year); CABG subgroup ranged from 142.8 pg/mL (5-year) to 175.9 pg/mL (1-year). Based on this analysis, we propose 150 pg/mL as threshold, approximating the median across all time points and both revascularisation strategies (median 153.4 pg/mL; range 119.4-233.1 pg/mL) while aligning with long-term mortality prediction cutoffs most relevant for sustained treatment effects. Among all biomarkers evaluated, NT-proBNP demonstrated the most consistent discriminative performance across intervention types, with excellent prognostic capacity at 5 years post-revascularisation. Patients with NT-proBNP <150 pg/mL (n=1,219) achieved 10-year survival of 90.6% versus 68.8% in those ≥150 pg/mL (n=1,026; fully adjusted HR 1.69, 95% CI: 1.41-2.03, p<0.001) in fully adjusted model including coronary disease severity and ejection fraction (Figure 3). Bootstrap validation (250 iterations) confirmed threshold robustness: optimal cutoff median 128.8 pg/mL (95% CI: 119.2-199.0), chosen 150 pg/mL at 74th percentile, negligible AUC optimism (-0.000).

The NT-proBNP × revascularisation interaction analysis (Figure 4) demonstrated significant effect modification (interaction term HR=1.569, 95% CI: 1.060-2.323, p=0.024), revealing four distinct prognostic phenotypes. Using patients without

revascularisation and NT-proBNP <150 pg/mL as reference, revascularized patients with low NT-proBNP (<150 pg/mL) showed improved survival (HR 0.64, 95% CI: 0.47-0.87, p=0.005). In contrast, elevated NT-proBNP (≥150 pg/mL) showed no mortality difference (HR 0.96, 95% CI: 0.71-1.30, p=0.782) and associated with survival outcomes comparable to those in non-revascularized patients with elevated NT-proBNP (HR 1.13, 95% CI: 0.93-1.38, p=0.219).

DISCUSSION

This comprehensive biomarker evaluation in CCS patients yields three principal findings: (1) among five biomarkers assessed, only hsTnT provides clinically meaningful diagnostic capacity for obstructive CAD (AUC 0.669), with performance comparable to RF-CL assessment (0.663) and demonstrating inverse relationship between baseline RF-CL and incremental discriminative value; (2) NT-proBNP emerges as superior prognostic biomarker with universal discrimination across all treatment categories; (3) NT-proBNP 150 pg/mL threshold identifies distinct prognostic phenotypes with differential survival outcomes by coronary revascularisation status. These findings extend our prior work (15) through direct comparison with the currently recommended PTP model, quantification of the incremental diagnostic value of hsTnT across RF-CL categories, and identification of a NT-proBNP threshold associated with differential survival patterns by revascularisation status—addressing critical needs for biomarker-guided treatment selection in contemporary CCS management.

HsTnT's diagnostic capacity reflects its direct relationship to myocardial injury from flow-limiting stenoses through repetitive ischemia-reperfusion (17,18), achieving

performance comparable to ESC 2024 PTP. Clinical likelihood-stratified analysis with the optimized 7.0 ng/L cutoff demonstrated marked heterogeneity: patients with very low pre-test likelihood (NRI=38.4%) showed greatest benefit, moderate benefit in low likelihood patients (NRI=19.3%), while intermediate/high likelihood patients (NRI=12.4%) showed the smallest benefit. This inverse gradient pattern likely reflects information content redundancy: in patients with multiple traditional risk factors and typical symptoms (high RF-CL), biomarker measurement adds limited new information, whereas in patients with few risk factors and atypical symptoms (low RF-CL), biomarker elevation meaningfully shifts probability estimates after adjustment for RF-CL variables. Importantly, safety validation demonstrated that false negative patients showed no excess mortality after adjustment for RF-CL variables, supporting the clinical applicability of this biomarker-guided approach. However, the substantial unadjusted mortality risk attributable to baseline cardiovascular risk factors underscores that safe reclassification does not obviate aggressive risk factor optimization or ongoing surveillance. A very low likelihood classification should, even after hsTnT implementation, guide deferred rather than omitted testing, with reassessment frequency individualized to baseline risk burden (1,2,23,24). These findings align with SCOT-HEART trial (n=1,430) demonstrating hsTnI improves pre-test probability estimation (OR 1.35, CI 1.25-1.46 per 2-fold increment) (27) and PROMISE (n=1,838) showing hsTnI independently predicts obstructive CAD presence and severity (OR 1.25 per IQR increase) (28), though neither specifically assessed incremental discriminative value beyond current ESC guideline-recommended diagnostic approaches or quantified category-specific benefits.

NT-proBNP emerged as the strongest mortality predictor across all patient categories, substantially outperforming hsTnT. This differential utility—hsTnT for diagnosis, NT-proBNP for prognosis—reflects distinct pathophysiology: hsTnT indicates injury relevant to obstruction detection, while NT-proBNP reflects ventricular stress, remodeling, and neurohumoral activation directly predicting mortality (3,4,16,20). NT-proBNP was the only biomarker maintaining prognostic discrimination across all therapeutic strategies. These findings contrast with the MICA study demonstrating hsTnI maintains independent prognostic value in stable angina patients (29). However, our results align with previous reports demonstrating robust MACE prediction by NT-proBNP in CCS patients with normal EF (30), while providing novel contributions: (1) treatment-interaction analysis demonstrating differential survival associations by NT-proBNP status and (2) 12.6-year median follow-up far exceeding typical 2–5-year investigations. Notably, biomarker-specific patterns emerged, with copeptin showing particularly strong performance in CABG patients. As a stable surrogate of arginine vasopressin release reflecting chronic neuroendocrine activation, copeptin's superior discriminative capacity in this subgroup may indicate more advanced coronary disease burden with greater myocardial dysfunction (19).

The proposed 150 pg/mL NT-proBNP cutoff is clinically meaningful, situated between ESC guideline thresholds for ruling out heart failure (125 pg/mL) and diagnosing acute heart failure (>300 pg/mL) (7), capturing early ventricular dysfunction and neurohumoral activation that precede overt heart failure (16,20). The significant interaction between NT-proBNP levels and revascularisation survival demonstrated differential prognostic patterns: revascularized patients with NT-proBNP <150 pg/mL

achieved 36% mortality reduction, while those above this threshold showed no mortality benefit—aligning with ISCHEMIA trial findings of no mortality benefit from routine invasive strategy in stable CAD with moderate-to-severe ischemia (22). Importantly, revascularisation provides benefits beyond mortality including symptom relief and improved quality of life, which may be particularly relevant for patients with elevated NT-proBNP. Clinically, this threshold may inform risk stratification: patients with NT-proBNP >150 pg/mL appear to represent a higher-risk phenotype requiring intensified medical therapy, closer surveillance, and potentially novel therapeutic approaches (8,23,24). This biomarker-guided approach parallels NT-proBNP-guided heart failure therapy (7), though prospective validation is needed before clinical implementation.

Several limitations warrant consideration. The single-center observational design with single timepoint measurements precludes definitive causal inference and lacks external validation in independent cohorts, limiting generalizability. Despite multivariable adjustment, residual confounding remains possible (Supplementary Table S5). Our analysis focused on mortality without assessing symptom relief, quality of life, or heart failure hospitalization—important revascularisation benefits particularly relevant for high-risk patients. We used invasive angiography with anatomical stenosis ≥50%—the established standard (25)—which demonstrates substantial discordance to functional relevance (26), potentially explaining moderate biomarker diagnostic performance. Guideline-recommended non-invasive imaging now preferred after RF-CL assessment (2) was unavailable, precluding comparison with currently recommended modalities. Outcome assessment was limited by unavailable cause-specific mortality and missing ICD implantation data. Relatively small treatment subgroup samples (particularly CABG,

n=267) may limit statistical power. While internal bootstrap validation supports model stability, external validation in diverse populations is required before clinical implementation. Finally, while 12.6-year follow-up is substantial, contemporary therapeutic advances may alter the prognostic landscape.

In conclusion, this comprehensive biomarker analysis demonstrates differential utility for diagnosis versus prognosis in chronic coronary syndrome. High-sensitivity troponin T provides RF-CL category-dependent incremental diagnostic value following an inverse pattern, with greatest benefit in very low likelihood patients, while NT-proBNP emerged as the universal prognostic biomarker across all treatment strategies. Critically, the 150 pg/mL NT-proBNP threshold demonstrated differential mortality patterns by coronary revascularisation status: patients below this cutoff showed improved outcomes with revascularisation, whereas elevated levels showed no mortality difference. Given the observational design with inherent confounding and structural group differences, these hypothesis-generating findings warrant prospective validation in randomized controlled trials to determine whether NT-proBNP can guide post-revascularisation management of CCS patients. These hypothesis-generating findings warrant prospective multicenter RCT validation to determine whether biomarker-guided strategies improve outcomes and cost-effectiveness in contemporary CCS management.

FUNDING

This work was supported by the Leipzig Research Centre for Civilization Diseases (LIFE), University of Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF), and by means of the Free State of Saxony within the framework of the excellence initiative.

ACKNOWLEDGEMENTS

The authors acknowledge all participants of the LIFE-Heart study for spending their time and donating blood, as well as for their continued participation in our follow-up endeavours. We thank Annegret Unger and Kay Olischer for running the study ambulance, and Ronny Dathe for database development.

CONFLICT OF INTEREST

Conflict of interest: none declared.

AUTHORS' CONTRIBUTIONS

AT and JN conceived and designed the study. AT, JT and HT contributed to data acquisition. AT, HK, and MS performed statistical analysis. AT drafted the manuscript. All authors (AT, JN, JT, HT, CS, DL, TL, AD, SH, HK, MS, TK) contributed to data interpretation, critically revised the manuscript for important intellectual content, and approved the final version for submission. AT takes responsibility for the integrity of the data and the accuracy of the data analysis.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the Leipzig Research Centre for Civilization Diseases (LIFE), University of Leipzig. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the corresponding author upon reasonable request and with permission of the LIFE study steering committee, subject to institutional data sharing agreements and ethical approval.

REFERENCES

1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425

2. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae176

3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. doi:10.1067/mcp.2001.113989

4. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115(8):949-952. doi:10.1161/CIRCULATIONAHA.106.683110

5. Chacko L, Howard JP, Rajkumar C, et al. Effects of percutaneous coronary intervention on death and myocardial infarction stratified by stable and unstable coronary artery disease: A meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes. 2020;13(2):e006363. doi:10.1161/CIRCOUTCOMES.119.006363

6. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-269. doi:10.1093/eurheartj/ehy462

7. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

8. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914

9. Scholz M, Doerr S, Henger S, et al. Cohort profile: the Leipzig LIFE Heart Study - phenotypes and cardiovascular disease risk factors in a representative population-based sample. Int J Epidemiol. 2017;46(2):425-426e. doi:10.1093/ije/dyw294

10. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606. doi:10.1016/s0002-9149(83)80105-2

11. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of Copeptin, a stable C-terminal vasopressin fragment in human plasma. Clin Chem. 2006;52(1):112-119. doi:10.1373/clinchem.2005.060038

12. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845.

13. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3

14. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11-21. doi:10.1002/sim.4085

15. Netto J, Teren A, Burkhardt R, et al. Biomarkers for non-invasive stratification of coronary artery disease and prognostic impact on long-term survival in patients with stable coronary heart disease. Nutrients. 2022;14(16):3433. doi:10.3390/nu14163433

16. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631-2639. doi:10.1056/NEJMoa055373

17. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54-61. doi:10.1373/clinchem.2011.165795

18. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361(26):2538-2547. doi:10.1056/NEJMoa0805299

19. Afşin A, Kaya H, Açar B, et al. Copeptin predicts coronary artery disease severity in patients with stable angina pectoris. Coron Artery Dis. 2016;27(1):34-39. doi:10.1097/MCA.0000000000000310

20. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107-2116. doi:10.1056/NEJMoa0707064

21. Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297(2):169-176. doi:10.1001/jama.297.2.169

22. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395-1407. doi:10.1056/NEJMoa1915922

23. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388

24. Leopold JA, Loscalzo J. Emerging role of precision medicine in cardiovascular disease. Circ Res. 2018;122(9):1302-1315. doi:10.1161/CIRCRESAHA.117.310782

25. Rosenthal RL. The 50% coronary stenosis. Am J Cardiol. 2015;115(8):1162-1165. doi:10.1016/j.amjcard.2015.01.553

26. Toth G, Hamilos M, Pyxaras S, et al. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. Eur Heart J. 2014;35(40):2831-2838. doi:10.1093/eurheartj/ehu094

27. Adamson PD, Hunter A, Madsen DM, et al. High-Sensitivity Cardiac Troponin I and the Diagnosis of Coronary Artery Disease in Patients With Suspected Angina Pectoris. Circ Cardiovasc Qual Outcomes. 2018;11(2):e004227. doi:10.1161/CIRCOUTCOMES.117.004227

28. Januzzi JL Jr, Suchindran S, Coles A, et al. High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD: Insights From the PROMISE Trial. JACC Cardiovasc Imaging. 2019;12(6):1047-1055. doi:10.1016/j.jcmg.2018.01.021

29. Wereski R, Adamson P, Shek Daud NS, et al. High-Sensitivity Cardiac Troponin for Risk Assessment in Patients With Chronic Coronary Artery Disease. J Am Coll Cardiol. 2023;82(6):473-485. doi:10.1016/j.jacc.2023.05.046

30. Liu HH, Cao YX, Jin JL, et al. Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study. Cardiovasc Diabetol. 2021;20(1):84. doi:10.1186/s12933-021-01271-0

FIGURE LEGENDS

Figure 1: Comparative Diagnostic Performance of hsTnT with ESC 2024 PTP (considering age, sex, symptoms plus diabetes, smoking, dyslipidemia, hypertension, family history of premature CAD). *Abbreviations: CAD, coronary artery disease, hsTnT, high-sensitivity Troponin T; ESC, European Society of Cardiology; PTP, pre-test probability; CRF, comprehensive cardiovascular risk factor model (i.e. ESC 2024 PTP variables plus LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycdrides; BMI, body mass index; WHR, waist-hip ratio; EF, left-ventricular ejection fraction; eGFR, estimated glomerular filtration rate).*

Figure 2: Treatment-Stratified Biomarker Prognostic Performance

Cox regression hazard ratios (per 1 SD increase) for five biomarkers across patient subgroups. Significant associations (p<0.05) shown in red (increased risk); non-significant in gray. NT-proBNP demonstrated universal prognostic utility across all categories. *Abbreviations: SD, standard deviation; CAD, coronary artery disease; hsTnT, high-sensitivity Troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; CRP, C-reactive protein; IL-6, Interleukin 6; LDL, low-density lipoprotein; HDL, high-density lipoprotein; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.*

Figure 3: Cox Proportional Hazard Survival Curves Stratified by NT-proBNP Cutoff 150 pg/mL Cox proportional hazards survival analysis demonstrating prognostic divergence based on NT-proBNP stratification at 150 pg/mL cutoff. Green curve: NT-proBNP <150 pg/mL (n=1,219 patients); Red curve: NT-proBNP ≥150 pg/mL (n=1,026 patients). Survival probabilities: 5-year (96.9% vs 87.4%), 10-year (90.6% vs 68.8%). *Abbreviations: NT-proBNP, N-terminal pro-B-type natriuretic peptide.*

Figure 4: Interaction Analysis - Revascularisation × NT-proBNP Forest plot demonstrating significant NT-proBNP × Revascularisation interaction (interaction term HR=1.569, 95% CI: 1.060-2.323, p=0.024). *Abbreviations: HR, hazard ratio; Revasc, Revascularisation i.e. PCI, percutaneous coronary intervention or CABG, coronary artery bypass grafting; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LDL, low-density lipoprotein; HDL, high-density lipoprotein; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.*

TABLES

Table 1. Baseline Characteristics of Study Population Stratified by Presence of Obstructive CCS

Characteristics	No oCAD N / Median	% / 25-75 IQR	oCAD N / Median	% / 25-75 IQR	p-value
N (%)	1363	60.6%	888	39.4%	-
Female sex (N)	605	44.4%	193	21.7%	< 0.001
Age (years)	61.6	53.8-69.8	65.7	57.3-71.1	< .001
BMI (kg/m²)	29.3	26.4-32.8	29.2	26.4-32.6	.370
Diabetes (N)	335	24.6%	302	34.0%	< .001
Family history with MI (N)	158	11.6%	113	12.7%	.439
Current smoker (N)	213	15.6%	188	21.2%	.003
Hypertension (N)	1179	86.5%	798	89.9%	.002
Antihypertensive medication (N)	1144	83.9%	776	87.4%	< .001
Lipid lowering medication (N)	459	33.7%	417	47.0%	< .001
LDL-cholesterol (mmol/l)	3.26	2.61-3.91	3.43	2.66-4.23	< .001
HDL-cholesterol (mmol/l)	1.32	1.10-1.61	1.22	1.01-1.48	< .001
Triglycerides (mmol/l)	1.63	1.13-2.41	1.74	1.27-2.48	< .001

Characteristics	No oCAD N / Median	% / 25-75 IQR	oCAD N / Median	% / 25-75 IQR	p-value
eGFR (in ml/min/1.73 m²)	87.84	75.24-96.84	84.91	71.9-94.8	< .001
Typical Angina	466	34.2%	437	49.2%	< .001
Atypical Angina	213	15.6%	85	9.6%	< .001
Non-anginal Chestpain	316	23.2%	109	12.3%	-
Dyspnoe NYHA > 1	317	23.3%	133	15.0%	< .001
No chest pain / no Dyspnoe	262	11.6%	193	8.6%	.407
ESC PTP 2024 5%	260	19.1	47	5.3	< .001
5% - 15%	637	46.7	313	35.2	
> 15%	466	34.2	528	59.2	
PCI	-	-	344	38.7	-
CABG	-	-	267	30.1	
hsTnT (pg/ml)	6.58	4.03-10.66	9.86	6.55-15.56	< .001
NT-pro BNP (pg/ml)	111.5	50.6-272.2	172.1	75.3-415.7	< .001
CRP (mg/l)	1.96	1.02-4.19	2.35	1.12-5.07	< .001
IL-6 (pg/ml)	2.38	1.50-4.02	2.99	1.80-5.50	< .001
Copeptin (pmol/l)	4.72	3.05-7.86	5.91	3.86-9.85	< .001

Abbreviations: oCAD, obstructive coronary artery disease; BMI, body mass index; MI, myocardial infarction; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular

filtration rate; NYHA, New York Heart Association; ESC, European Society of Cardiology; PTP, pre-test probability; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; hsTnT, high-sensitivity Troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; CRP, C-reactive protein; IL-6, Interleukin 6; IQR, interquartile range.

Table 2. Reclassification Analysis by hsTnT 7.0 ng/L Cutoff Stratified by RF-CL Category. Category-specific NRI and IDI values demonstrating inverse gradient relationship. Event NRI quantifies correct upward reclassification of patients with obstructive CAD. Non-event NRI quantifies correct downward reclassification of patients without obstructive CAD. Bootstrap validation with 500 iterations.

RF-CL Category	Categorical NRI (%)	95% CI	Event NRI (%)	Non-Event NRI (%)	IDI 95% CI (%)
Very Low (<5%)	38.4	28.9-47.8	+19.2	+19.2	6.3 (4.8-7.9)
Obstructive CAD					
Low (5-15%)	19.3	12.7-26.0	+12.1	+7.2	4.2 (2.9-5.5)
Obstructive CAD					
Intermediate/High (>15%)	12.4	6.8-18.1	+8.4	+4.0	2.6 (1.4-3.8)
Obstructive CAD					

Abbreviations: hsTnT, high-sensitivity Troponin T; RF-CL, risk-factor weighted clinical likelihood; NRI, net reclassification improvement; IDI, integrated discrimination improvement; CAD, coronary artery disease

SUPPLEMENTARY MATERIAL

Supplementary Figure S1A: Model Calibration Plots

Supplementary Figure S1B: Decision Curve Analysis

Supplementary Table S1: Detailed Reclassification Metrics by RF-CL Category

Supplementary Table S2: AUC Improvements by RF-CL Category

Supplementary Table S3: Detailed Reclassification Patterns

Supplementary Table S4: Safety Analysis of False Negative Patients

Supplementary Table S5: Potential Confounding Variables

STROBE Checklist (as per EQUATOR Network requirements)

— END OF MANUSCRIPT —

Biomarker Predictive Values for Long Term Survival

Cox Regression Analysis by Treatment Strategy (per 1 SD increase, 95% CI)

	HR (95% CI)	P-value
Overall Sample		
hsTnT	1.261 (1.178-1.349)	<0.001
NT-proBNP	1.220 (1.139-1.306)	<0.001
Copeptin	1.124 (1.057-1.233)	p=0.011
IL-6	1.162 (1.101-1.225)	p<0.001
hsCRP	1.154 (1.063-1.254)	p<0.001
No obstructive CAD		
hsTnT	1.349 (1.206-1.506)	p<0.001
NT-proBNP	1.220 (1.097-1.400)	p=0.007
Copeptin	1.024 (0.903-1.162)	p=0.522
IL-6	1.201 (1.111-1.296)	p<0.001
hsCRP	1.291 (1.156-1.443)	p<0.001
Obstructive CAD: OMT		
hsTnT	1.168 (0.957-1.407)	p=0.154
NT-proBNP	1.488 (1.165-1.901)	p<0.001
Copeptin	1.136 (0.883-1.460)	p=0.154
IL-6	1.250 (1.074-1.453)	p=0.004
hsCRP	1.095 (0.880-1.363)	p=0.419
Obstructive CAD: PCI		
hsTnT	1.250 (1.044-1.504)	p=0.016
NT-proBNP	1.220 (1.020-1.458)	p=0.029
Copeptin	1.042 (0.822-1.324)	p=0.730
IL-6	1.036 (0.875-1.186)	p=0.730
hsCRP	0.979 (0.784-1.255)	p=0.886
Obstructive CAD: CABG		
hsTnT	1.198 (1.044-1.361)	p=0.008
NT-proBNP	1.220 (1.045-1.419)	p=0.010
Copeptin	1.389 (1.136-1.697)	p<0.001
IL-6	1.157 (1.039-1.291)	p=0.008
hsCRP	1.000 (0.832-1.216)	p=0.983

... Protective   Hazard Ratio (95% CI)   Risk ...

Adjusted for Confounders:
Clinical variables: Age, Sex, Smoking status, Diabetes, Body mass index, Waist-hip ratio, Hypertension
Laboratory parameters: LDL cholesterol, HDL cholesterol, Triglycerides, Glomerular filtration rate
Medications: Cholesterol lowering therapy, Antihypertensive therapy
Cardiovascular parameters: Ejection fraction, Gensini score, Number of coronary vessels with ≥50% stenosis,
Family history of myocardial infarction before 60 years of age

Biomarker standard deviations: hsTnT = 8.7 ng/L, NT-proBNP = 198.8 pg/mL, Copeptin = 3.0 pmol/L, IL-6 = 4.2 pg/mL, hsCRP = 2.1 mg/L

Cox Proportional Hazard Survival Curves
Stratified Analysis by NT-proBNP (Cutoff 150 pg/mL)

Survival Estimates:
• 5-year: Low NT-proBNP 96.9% vs High NT-proBNP 87.4%
• 10-year: Low NT-proBNP 90.6% vs High NT-proBNP 68.8%

Fully Adjusted Hazard Ratio:
• NT-proBNP ≥150 vs <150 pg/mL: HR = 1.69 (95% CI: 1.41-2.03)
• P < 0.001

Legend:
— NT-proBNP <150 pg/mL
— NT-proBNP ≥150 pg/mL

Group	0 years	2 years	4 years	6 years	8 years	10 years	12 years
NT-proBNP <150 pg/mL	1219	1209	1189	1174	1146	939	828
NT-proBNP ≥150 pg/mL	1026	973	930	867	798	629	515

Cardiac Biomarkers to Refine Pre-Test Probability and Predict Revascularization Benefits

LIFE-Heart Study: 2,251 Patients admitted for suspected Chronic Coronary Syndrome / 12.6 Year median Follow-up

A. Biomarker Performance for Detection of Coronary Obstruction

Comparison Biomarkers and ESC 2024 RF-CL Model

Incremental Value by hsTnT cutoff 7.0 ng/L across RF-CL categories

B. NT-proBNP indicates Improved Survival after Revascularisation

Lower Risk — Higher Risk

NT-proBNP <150 pg/mL No Revasc — Reference

NT-proBNP >=150 pg/mL No Revasc — HR=1.13 (95% CI: 0.93-1.38), p=0.219

NT-proBNP >=150 pg/mL + Revasc — HR=0.96 (95% CI: 0.71-1.30), p=0.782

NT-proBNP <150 pg/mL + Revasc — HR=0.64 (95% CI: 0.47-0.87), p=0.005

Hazard Ratio (95% CI)

Hazard ratios for mortality by NT-proBNP status and treatment

C. Clinical Translation: Biomarker-Guided Precision Medicine

KEY FINDINGS

hsTnT: Diagnostic Marker
AUC 0.669 for Obstructive CAD Detection
Comparable to ESC 2024 RF-CL (AUC 0.663)

NT-proBNP: Superior Prognostic Marker

Universal Mortality Predictor Across All Treatments

NT-proBNP <150 pg/mL:
36% Survival Increase associated with Revascularisation
NT-proBNP >=150: no difference in Survival with Revascularisation

CLINICAL IMPLICATION

**Biomarker-Guided Diagnostics in low-risk Patients
and Improved Risk Stratification**

**NT-proBNP <150 associates with Improved Survival
after Revascularisation**